LB Pharmaceuticals to end prior resale registration

The company says it has obtained well-known seasoned issuer status and is eligible to register securities on Form S-3ASR.

Rhea-AI Filing Summary

LB Pharmaceuticals Inc. is terminating the effectiveness of its Form S-1 registration and removing securities that remain unsold. The S-1 had registered the offer and resale of up to an aggregate of 4,778,491 common shares by selling stockholders. Offers and sales under the S-1 terminate upon effectiveness of the Form S-3ASR, which registers unsold or unissued shares covered by the S-1.

Filing Explained

The effective S-3ASR permits the company and selling holders to offer securities in the future, but has zero reported usage as of October 1, 2026; this filing establishes registration capacity, not a completed sale or issuance under the shelf.

Key Figures

Previously registered resale shares: Up to an aggregate of 4,778,491 shares Common stock par value: $0.0001 per share S-1 effective date: April 14, 2026

3 metrics

Previously registered resale shares Up to an aggregate of 4,778,491 shares S-1 offer and resale by selling stockholders

Common stock par value $0.0001 per share Common stock covered by the S-1

S-1 effective date April 14, 2026 Original registration statement

Key Terms

Post-Effective Amendment, well-known seasoned issuer status, Form S-3ASR

3 terms

Post-Effective Amendment regulatory

"This Post-Effective Amendment No. 1"

A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.

well-known seasoned issuer status regulatory

"obtained well-known seasoned issuer status"

Form S-3ASR regulatory

"register its securities under a new registration statement on Form S-3ASR"

Form S-3ASR is a type of SEC registration that lets large, well-known public companies pre-register securities so they can be sold quickly when needed, similar to having a pre-approved credit line they can draw on at short notice. For investors, it matters because it signals a company's readiness to raise cash fast, which can affect share supply and price (dilution) and reveal how easily the company can fund growth or handle short-term needs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did LBRX's S-1 register for resale?

The S-1 registered the offer and resale of up to an aggregate of 4,778,491 shares of common stock by the selling stockholders identified in that registration.

When do offers and sales under LBRX's S-1 registration end?

Offers and sales under the S-1 terminate upon effectiveness of the Form S-3ASR. The amendment also removes from registration securities registered under the S-1 that remain unsold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 06:01 PM Accepted by SEC EDGAR 10/01/2026 - 04:08 PM Learn about SEC filing dates

As filed with the Securities and Exchange Commission on October 1, 2026

Registration No. 333-294900

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Post-Effective Amendment No. 1

to

FORM S-1

REGISTRATION STATEMENT

Under

The Securities Act of 1933

LB Pharmaceuticals Inc

(Exact name of Registrant as specified in its charter)

Delaware		2834		81-1854347
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification Number)

One Pennsylvania Plaza, Suite 1025

New York, NY 10119

Tel: (212) 605-0300

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

Heather Turner

Chief Executive Officer

1 Pennsylvania Plaza, Suite 1025

New York, NY 10119

Tel: (212) 605-0300

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Divakar Gupta

Brandon Fenn

Marc Recht

Minkyu Park

Cooley LLP

55 Hudson Yards

New York, NY 10001

Tel: (212) 479-6000

Approximate date of commencement of proposed sale to the public: Not applicable. The Registrant is filing this post-effective amendment to remove from registration any securities registered hereunder that remain unsold.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”), relates to the Registration Statement on Form S-1 (File No. 333-294900) (the “S-1 Registration Statement”), filed by LB Pharmaceuticals Inc, a Delaware corporation (the “Registrant”), on April 6, 2026, with the Securities and Exchange Commission (the “SEC”) to register the offer and resale of up to an aggregate of 4,778,491 shares of the Registrant’s common stock, par value $0.0001 per share, by the selling stockholders identified in the S-1 Registration Statement (the “Selling Stockholders”). The Registration Statement was declared effective on April 14, 2026.

The Registrant has determined that it has obtained well-known seasoned issuer status as of the date hereof and is now eligible to register its securities under a new registration statement on Form S-3ASR (the “S-3 Registration Statement”). In connection with the Registrant filing the S-3 Registration Statement with the SEC, which, among other things, registers any and all unsold or unissued shares of common stock by the Selling Stockholders under the S-1 Registration Statement, all offers and sales of the Registrant’s securities registered pursuant to the S-1 Registration Statement are being terminated.

Any and all offerings of the Registrant’s securities pursuant to the S-1 Registration Statement are being terminated upon effectiveness of the S-3 Registration Statement. Accordingly, the Registrant hereby terminates the effectiveness of the S-1 Registration Statement. In addition, in accordance with undertakings made by the Registrant in the S-1 Registration Statement to remove from registration, by means of a post-effective amendment, any securities being registered which remain unsold at the termination of the offering, the Registrant hereby removes from registration all securities registered under the S-1 Registration Statement that remain unsold under the S-1 Registration Statement as of the date hereof. The S-1 Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on October 1, 2026.

LB PHARMACEUTICALS INC
By:		/s/ Heather Turner
		Heather Turner Chief Executive Officer